Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SarcVac Combined With Tumor-specific Lymphocytes and PD-1 Antibody in Advanced Sarcoma
NCT07648069Phase 1Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2024
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial in soft tissue sarcoma (STS) and osteosarcoma (OS) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Incidence and severity of adverse events at 120 days. Started Sep 2024; status: recruiting.
02
Conditions
soft tissue sarcoma (STS)osteosarcoma (OS)
Beyond the preview
Go deeper on NCT07648069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07648069.